Indication

with prednisolone for the treatment of adult men with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

Medicine details

Medicine name:
abiraterone acetate (Zytiga)
SMC ID:
SMC2215
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q1 2020
SMC meeting date:
Q4 2019
Patient group submission deadline:
30 September 2019